Annales De Dermatologie Et De Venereologie最新文献

英文中文

Anti-interleukin-23-associated alopecia areata in patients with psoriasis: two cases and a literature review 银屑病患者抗白介素-23相关性斑秃2例及文献复习

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-22 DOI: 10.1016/j.annder.2025.103374

Y. Hameg, S. Vildy, E. Mahé, the Groupe de Recherche sur le Psoriasis GRPso of the Société Française de Dermatologie

引用次数: 0

The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study 时间对晚期黑色素瘤患者免疫治疗的影响及其疗效：一项回顾性观察性研究

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-19 DOI: 10.1016/j.annder.2025.103371

M. Amici , E. Neveu , F. Poizeau , J. Edeline , T. Lesimple , E. Oger , G. Danton , A. Dupuy , M. Fouchard

Background

Certain publications suggest that immunotherapy would be more effective if it were synchronised with the circadian oscillations of the immune system. We hypothesised that late treatment delivery in melanoma patients would correlate with worse survival outcomes.

Patients and methods

We conducted a monocentric retrospective study in patients with advanced cutaneous melanoma receiving immune checkpoint inhibitors as first-line therapy. We used the median clock time of all infusions (11:00) as the cut-off point to differentiate morning from afternoon. Patients were allocated to the morning or afternoon group depending on whether they had received >50% of their infusions before or after 11:00. A propensity score was calculated. Timing groups were assessed for association with overall and progression-free survival using a Cox proportional hazards model, survival curves were compared, and treatment-related adverse events (AEs) were analysed.

Results

We included 154 patients treated with frontline immunotherapy in a metastatic setting from 1 January 2013 to 1 January 2022, with a median age of 67 years (interquartile range: 56–75). Late treatment delivery was associated neither with worse overall survival (median not reached [34.9-not estimable] vs. 70.8 months; hazard ratio (HR) = 0.94 [0.63–1.39]) nor worse progression-free survival (22.3 vs. 26.5; HR = 0.99 [0.71–1.38]), and there were no differences in survival outcomes between the groups. Severe treatment-related AEs were significantly more frequent in the afternoon group than in the morning group (33 [34%] vs. 6 [11%] respectively, weighted p-value = 0.004).

Conclusion

Timing was not associated with worse efficacy outcomes, but morning administration appears to improve safety.

背景某些出版物指出，如果免疫疗法与免疫系统的昼夜节律同步，则会更加有效。患者和方法我们对接受免疫检查点抑制剂一线治疗的晚期皮肤黑色素瘤患者进行了一项单中心回顾性研究。我们将所有输液的中位时钟时间（11:00）作为区分上午和下午的分界点。根据患者50%的输液时间是在11:00之前还是之后，将他们分配到上午组还是下午组。计算倾向得分。结果我们纳入了2013年1月1日至2022年1月1日期间接受一线免疫疗法治疗的154名转移性患者，中位年龄为67岁（四分位间距：56-75岁）。晚期治疗与总生存期（中位数未达到[34.9-无法估计]对70.8个月；危险比（HR）=0.94[0.63-1.39]）和无进展生存期（22.3对26.5；HR=0.99[0.71-1.38]）均无关系，两组间的生存结果也无差异。下午组发生严重治疗相关 AEs 的频率明显高于上午组（分别为 33 [34%] 对 6 [11%]，加权 p 值 = 0.004）。

{"title":"The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study","authors":"M. Amici , E. Neveu , F. Poizeau , J. Edeline , T. Lesimple , E. Oger , G. Danton , A. Dupuy , M. Fouchard","doi":"10.1016/j.annder.2025.103371","DOIUrl":"10.1016/j.annder.2025.103371","url":null,"abstract":"<div><h3>Background</h3><div>Certain publications suggest that immunotherapy would be more effective if it were synchronised with the circadian oscillations of the immune system. We hypothesised that late treatment delivery in melanoma patients would correlate with worse survival outcomes.</div></div><div><h3>Patients and methods</h3><div>We conducted a monocentric retrospective study in patients with advanced cutaneous melanoma receiving immune checkpoint inhibitors as first-line therapy. We used the median clock time of all infusions (11:00) as the cut-off point to differentiate morning from afternoon. Patients were allocated to the morning or afternoon group depending on whether they had received >50% of their infusions before or after 11:00. A propensity score was calculated. Timing groups were assessed for association with overall and progression-free survival using a Cox proportional hazards model, survival curves were compared, and treatment-related adverse events (AEs) were analysed.</div></div><div><h3>Results</h3><div>We included 154 patients treated with frontline immunotherapy in a metastatic setting from 1 January 2013 to 1 January 2022, with a median age of 67 years (interquartile range: 56–75). Late treatment delivery was associated neither with worse overall survival (median not reached [34.9-not estimable] vs. 70.8 months; hazard ratio (HR) = 0.94 [0.63–1.39]) nor worse progression-free survival (22.3 vs. 26.5; HR = 0.99 [0.71–1.38]), and there were no differences in survival outcomes between the groups. Severe treatment-related AEs were significantly more frequent in the afternoon group than in the morning group (33 [34%] vs. 6 [11%] respectively, weighted <em>p</em>-value = 0.004).</div></div><div><h3>Conclusion</h3><div>Timing was not associated with worse efficacy outcomes, but morning administration appears to improve safety.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103371"},"PeriodicalIF":3.1,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leser-Trélat sign on BRAF inhibitors BRAF抑制剂的治疗效果较好

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-19 DOI: 10.1016/j.annder.2025.103368

C. Decaestecker , R. Levard , J.-M. L’Orphelin

引用次数: 0

Clinical course and prognostic disparities of pyoderma gangrenosum based on underlying disease: A long-term comparative study in 124 patients 基于基础疾病的坏疽性脓皮病的临床病程和预后差异：124例患者的长期比较研究

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-07 DOI: 10.1016/j.annder.2025.103364

D. Bar , S. Baum , A. Druyan , R. Mansour , A. Barzilai , M. Lidar

Background and objectives

Pyoderma gangrenosum (PG) is associated with inflammatory bowel disease (IBD), autoimmune and connective tissue diseases, and hematologic malignancies. The impact of these underlying diseases on the clinical course and outcomes of PG remains poorly understood. This study investigates the influence of systemic disease associations on the progression, treatment response, and prognosis of PG.

Patients and methods

This study followed a cohort of 124 patients diagnosed with PG at a multidisciplinary referral institution between 2007 and 2024. Patients were stratified into four groups: IBD-associated PG (n = 52), autoimmune and connective tissue disease-associated PG (n = 24), hematologic malignancy-associated PG (n = 15), and idiopathic PG (n = 33). Outcomes, including remission and relapse rates, were analyzed using Kaplan-Meier survival curves and Cox proportional hazards models.

Results

IBD-associated PG had the most favorable outcomes, with 75% of patients achieving remission at 12 months (M12) (Hazard Ratio [HR]: 2.56; 95% Confidence Interval [95%CI]: 1.49–4.35). Autoimmune and connective tissue disease-associated PG was the most treatment-refractory, with only 8.3% achieving remission at M12 (HR: 0.21; 95% CI: 0.10–0.50). Relapse occurred in 26.1% of patients, with no significant difference across the groups (p = 0.8). Bullous PG, predominantly linked to hematologic malignancies, exhibited accelerated healing but also a high rate of malignant transformations near PG onset.

Conclusions

IBD-associated PG followed a more favorable clinical course compared to autoimmune and connective tissue diseases or hematologic conditions, highlighting the importance of tailored treatment approaches based on underlying disease associations.

背景与目的坏疽性皮肤病（PG）与炎症性肠病（IBD）、自身免疫性和结缔组织疾病以及血液系统恶性肿瘤相关。这些潜在疾病对PG的临床过程和结局的影响仍然知之甚少。本研究探讨了全身性疾病关联对PG进展、治疗反应和预后的影响。患者和方法本研究随访了2007年至2024年间在多学科转诊机构诊断为PG的124例患者。患者被分为四组：ibd相关PG (n = 52)，自身免疫和结缔组织疾病相关PG (n = 24)，血液恶性肿瘤相关PG (n = 15)，特发性PG （n = 33）。结果，包括缓解率和复发率，使用Kaplan-Meier生存曲线和Cox比例风险模型进行分析。结果sibd相关PG的预后最有利，75%的患者在12 个月（M12）时获得缓解(风险比[HR]: 2.56；95%置信区间[95% ci]: 1.49-4.35)。自身免疫性和结缔组织疾病相关的PG是最难治疗的，只有8.3%的患者在M12时获得缓解(HR: 0.21；95% ci: 0.10-0.50)。复发发生率为26.1%，两组间无显著差异（p = 0.8）。大疱性PG，主要与血液系统恶性肿瘤有关，表现出加速愈合，但在PG发病附近也有很高的恶性转化率。结论与自身免疫性和结缔组织疾病或血液学疾病相比，sibd相关的PG具有更有利的临床病程，突出了基于潜在疾病关联的量身定制治疗方法的重要性。

{"title":"Clinical course and prognostic disparities of pyoderma gangrenosum based on underlying disease: A long-term comparative study in 124 patients","authors":"D. Bar , S. Baum , A. Druyan , R. Mansour , A. Barzilai , M. Lidar","doi":"10.1016/j.annder.2025.103364","DOIUrl":"10.1016/j.annder.2025.103364","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Pyoderma gangrenosum (PG) is associated with inflammatory bowel disease (IBD), autoimmune and connective tissue diseases, and hematologic malignancies. The impact of these underlying diseases on the clinical course and outcomes of PG remains poorly understood. This study investigates the influence of systemic disease associations on the progression, treatment response, and prognosis of PG.</div></div><div><h3>Patients and methods</h3><div>This study followed a cohort of 124 patients diagnosed with PG at a multidisciplinary referral institution between 2007 and 2024. Patients were stratified into four groups: IBD-associated PG (<em>n</em> = 52), autoimmune and connective tissue disease-associated PG (<em>n</em> = 24), hematologic malignancy-associated PG (<em>n</em> = 15), and idiopathic PG (<em>n</em> = 33). Outcomes, including remission and relapse rates, were analyzed using Kaplan-Meier survival curves and Cox proportional hazards models.</div></div><div><h3>Results</h3><div>IBD-associated PG had the most favorable outcomes, with 75% of patients achieving remission at 12 months (M12) (Hazard Ratio [HR]: 2.56; 95% Confidence Interval [95%CI]: 1.49–4.35). Autoimmune and connective tissue disease-associated PG was the most treatment-refractory, with only 8.3% achieving remission at M12 (HR: 0.21; 95% CI: 0.10–0.50). Relapse occurred in 26.1% of patients, with no significant difference across the groups (<em>p</em> = 0.8). Bullous PG, predominantly linked to hematologic malignancies, exhibited accelerated healing but also a high rate of malignant transformations near PG onset.</div></div><div><h3>Conclusions</h3><div>IBD-associated PG followed a more favorable clinical course compared to autoimmune and connective tissue diseases or hematologic conditions, highlighting the importance of tailored treatment approaches based on underlying disease associations.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103364"},"PeriodicalIF":3.1,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143786023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lacosamide-induced nodulocystic acne with keloid scarring 拉科胺致结节性痤疮伴瘢痕疙瘩

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-05 DOI: 10.1016/j.annder.2025.103361

G. Gasparini, C. Cabona, B. Piazza, I. Pappalardo, F. Villani, E. Cozzani

引用次数: 0

Palmar squamous cell carcinoma 手掌鳞状细胞癌

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-04-02 DOI: 10.1016/j.annder.2025.103362

M.A. Aristizabal, J.C. Sluzevich, I. Roman, E. Singer

引用次数: 0

Efficacy and safety of spesolimab in the treatment of generalized pustular psoriasis in elderly patients spesolimab治疗老年广泛性脓疱性银屑病的疗效和安全性

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-03-28 DOI: 10.1016/j.annder.2025.103363

G. Russo , S. Dumont , S. Menzinger, L. Rocher, E. Laffitte

引用次数: 0

Hyperglycemic hyperosmolar coma induced by alpelisib in PIK3CA-related overgrowth spectrum (PROS) pik3ca相关过度生长谱（PROS）中alpelisib诱导的高血糖性高渗性昏迷

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-03-28 DOI: 10.1016/j.annder.2025.103354

M. Deriouich, A. Dompmartin, G. Canaud, J.-M. L’Orphelin

引用次数: 0

Management of hypertensive leg ulcers: A French national survey 高血压腿溃疡的管理：一项法国全国调查

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-03-17 DOI: 10.1016/j.annder.2025.103353

Y. Zerdani , H. Nguyen-Chi , J.-B. Monfort , P. Senet , E. Tella , E. Mahé , The Groupe Angiodermatologie (GAD) of the Société Française de Dermatologie

Background

Hypertensive leg ulcers (HLUs) are superficial, rapidly spreading, necrotic ulcers that are frequently resistant to standard local wound care. The available literature on HLU management is relatively poor. This survey-based study aimed to evaluate the management of HLUs in France.

Methods

A questionnaire was sent in December 2019 to all members of the Angiodermatology Group of the French Society of Dermatology. The questionnaire collected information about physicians and their department, and about their management of HLUs, including examinations and specific and non-specific topical and systemic treatments.

Results

Forty-four physicians responded. The most frequently performed examinations were lower-limb arterial Doppler (88.6%), ankle-brachial pressure index tests (83.7%) and venous Doppler (60.5%). Blood sampling for autoimmunity testing was requested by 27.3% of physicians and skin biopsy by 20.5%. The most frequently used first-line therapy was skin grafting (97.7%). Other treatments included topical steroids (58.1%), negative-pressure therapy (15.9%), electrostimulation (15.9%), auto-haemotherapy (14.0%), and iloprost (11.4%). The mechanism of action of electrostimulation is not very clear. Its main benefit lies in controlling the pain of HLU. Iloprost appears to be an interesting vasodilator although it has not been validated to date. An additional antiplatelet agent was proposed by 19.0% of the physicians and modification of anticoagulant treatment (use of a vitamin K antagonist in addition to direct oral anticoagulants) was proposed by 19.5% of physicians.

Discussion

The survey results showed that HLU evaluation involved searching for associated peripheral arterial disease and that HLU management in France was disparate. Skin grafting was the sole consensual treatment and was generally used as a first-line option. Other treatments require further evaluation. Management disparities could be reduced by the drafting and publication of a consensus guideline to harmonise HLU management.

背景：高血压性腿部溃疡（hlu）是一种浅表、迅速扩散的坏死性溃疡，通常对标准的局部伤口护理无效。现有的关于HLU管理的文献相对较少。这项基于调查的研究旨在评估法国hlu的管理。方法于2019年12月向法国皮肤病学会血管皮肤病组所有成员发送问卷。问卷收集了医生及其科室的信息，以及他们对hlu的管理，包括检查、特异性和非特异性局部和全身治疗。结果44名医生回应。最常见的检查是下肢动脉多普勒（88.6%）、踝臂压指数（83.7%）和静脉多普勒（60.5%）。27.3%的医生要求采血进行自身免疫检测，20.5%的医生要求皮肤活检。最常用的一线治疗是植皮（97.7%）。其他治疗包括外用类固醇（58.1%）、负压治疗（15.9%）、电刺激（15.9%）、自体血液治疗（14.0%）和伊洛前列素（11.4%）。电刺激的作用机制尚不十分清楚。它的主要好处在于控制了HLU的痛苦。伊洛前列素似乎是一种有趣的血管扩张剂，尽管迄今尚未得到证实。19.0%的医生建议使用一种额外的抗血小板药物，19.5%的医生建议修改抗凝治疗（在直接口服抗凝药物的基础上使用维生素K拮抗剂）。调查结果显示，HLU评估涉及寻找相关的外周动脉疾病，法国的HLU管理存在差异。皮肤移植是唯一的双方同意的治疗方法，通常作为一线选择。其他治疗方法需要进一步评估。可以通过起草和出版协调卫生机构管理的协商一致准则来减少管理上的差异。

{"title":"Management of hypertensive leg ulcers: A French national survey","authors":"Y. Zerdani , H. Nguyen-Chi , J.-B. Monfort , P. Senet , E. Tella , E. Mahé , The Groupe Angiodermatologie (GAD) of the Société Française de Dermatologie","doi":"10.1016/j.annder.2025.103353","DOIUrl":"10.1016/j.annder.2025.103353","url":null,"abstract":"<div><h3>Background</h3><div>Hypertensive leg ulcers (HLUs) are superficial, rapidly spreading, necrotic ulcers that are frequently resistant to standard local wound care. The available literature on HLU management is relatively poor. This survey-based study aimed to evaluate the management of HLUs in France.</div></div><div><h3>Methods</h3><div>A questionnaire was sent in December 2019 to all members of the Angiodermatology Group of the French Society of Dermatology. The questionnaire collected information about physicians and their department, and about their management of HLUs, including examinations and specific and non-specific topical and systemic treatments.</div></div><div><h3>Results</h3><div>Forty-four physicians responded. The most frequently performed examinations were lower-limb arterial Doppler (88.6%), ankle-brachial pressure index tests (83.7%) and venous Doppler (60.5%). Blood sampling for autoimmunity testing was requested by 27.3% of physicians and skin biopsy by 20.5%. The most frequently used first-line therapy was skin grafting (97.7%). Other treatments included topical steroids (58.1%), negative-pressure therapy (15.9%), electrostimulation (15.9%), auto-haemotherapy (14.0%), and iloprost (11.4%). The mechanism of action of electrostimulation is not very clear. Its main benefit lies in controlling the pain of HLU. Iloprost appears to be an interesting vasodilator although it has not been validated to date. An additional antiplatelet agent was proposed by 19.0% of the physicians and modification of anticoagulant treatment (use of a vitamin K antagonist in addition to direct oral anticoagulants) was proposed by 19.5% of physicians.</div></div><div><h3>Discussion</h3><div>The survey results showed that HLU evaluation involved searching for associated peripheral arterial disease and that HLU management in France was disparate. Skin grafting was the sole consensual treatment and was generally used as a first-line option. Other treatments require further evaluation. Management disparities could be reduced by the drafting and publication of a consensus guideline to harmonise HLU management.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103353"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy 0.1%他克莫司在靶向治疗时代治疗白癜风的价值

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2025-03-11 DOI: 10.1016/j.annder.2025.103352

A. Duplaine , J. Tannous , J. Seneschal , K. Ezzedine , T. Passeron , N. Dupin , G. Quereux , M. Beylot-Barry , O. Chosidow , B. Guillot , for the Centre of Evidence of the French Society of Dermatology

Background

Vitiligo, a prevalent depigmenting condition, affects both adults and children, significantly impacting their quality of life. The standard treatment approach involves the application of topical corticosteroids in conjunction with narrow-band ultraviolet B (UVB) phototherapy. A novel topical treatment, ruxolitinib (a Janus kinase inhibitor), has recently received approval. Notwithstanding the absence of marketing authorization for this particular indication in France, numerous practitioners have adopted the use of tacrolimus ointment 0.1% for the treatment of vitiligo, frequently in conjunction with phototherapy. The objective of this study is to present the benefit/risk ratio of tacrolimus in the treatment of vitiligo.

Methods

A comprehensive literature search was conducted by the Centre of Evidence (CDP) of the French Society of Dermatology (SFD) to ascertain the efficacy and safety of topical calcineurin inhibitors (TCIs) in vitiligo. The search strategy encompassed meta-analyses (MAs) and prospective multicentric cohort studies.

Results

Literature data – in particular three meta-analyses and one randomised controlled trial – confirm the superiority of tacrolimus versus placebo and its non-inferiority versus super-potent topical corticosteroids. In a subgroup analysis, tacrolimus suggests superior efficacy in children and in facial vitiligo. The combined use of tacrolimus and phototherapy exhibited synergistic efficacy.

Conclusion

Notwithstanding the market access of topical ruxolitinib, tacrolimus remains a viable treatment option for vitiligo, as substantiated by extant efficacy and safety in the literature. A recent decision of the French National Agency for the Safety of Medicines and Health Products (ANSM) authorized the compassionate prescription of tacrolimus and its reimbursement for patients.

白癜风是一种常见的脱色疾病，影响成人和儿童，严重影响他们的生活质量。标准的治疗方法包括应用局部皮质类固醇结合窄带紫外线B （UVB）光疗。一种新的局部治疗药物ruxolitinib（一种Janus激酶抑制剂）最近获得批准。尽管在法国没有这种特殊适应症的上市许可，许多从业者已经采用0.1%他克莫司软膏治疗白癜风，经常与光疗结合使用。本研究的目的是介绍他克莫司治疗白癜风的获益/风险比。方法通过法国皮肤学会（SFD）证据中心（CDP）进行全面的文献检索，确定外用钙调磷酸酶抑制剂（tci）治疗白癜风的有效性和安全性。检索策略包括荟萃分析（MAs）和前瞻性多中心队列研究。结果：文献数据——特别是三项荟萃分析和一项随机对照试验——证实了他克莫司相对于安慰剂的优越性及其相对于超强外用皮质类固醇的非劣效性。在亚组分析中，他克莫司对儿童和面部白癜风的疗效更佳。他克莫司与光疗联合使用具有协同作用。结论尽管外用ruxolitinib已进入市场，但他克莫司仍是白癜风的可行治疗选择，其有效性和安全性已在文献中得到证实。法国国家药品和保健品安全管理局（ANSM）最近的一项决定授权他克莫司的同情处方及其对患者的报销。

{"title":"Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy","authors":"A. Duplaine , J. Tannous , J. Seneschal , K. Ezzedine , T. Passeron , N. Dupin , G. Quereux , M. Beylot-Barry , O. Chosidow , B. Guillot , for the Centre of Evidence of the French Society of Dermatology","doi":"10.1016/j.annder.2025.103352","DOIUrl":"10.1016/j.annder.2025.103352","url":null,"abstract":"<div><h3>Background</h3><div>Vitiligo, a prevalent depigmenting condition, affects both adults and children, significantly impacting their quality of life. The standard treatment approach involves the application of topical corticosteroids in conjunction with narrow-band ultraviolet B (UVB) phototherapy. A novel topical treatment, ruxolitinib (a Janus kinase inhibitor), has recently received approval. Notwithstanding the absence of marketing authorization for this particular indication in France, numerous practitioners have adopted the use of tacrolimus ointment 0.1% for the treatment of vitiligo, frequently in conjunction with phototherapy. The objective of this study is to present the benefit/risk ratio of tacrolimus in the treatment of vitiligo.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted by the Centre of Evidence (CDP) of the French Society of Dermatology (SFD) to ascertain the efficacy and safety of topical calcineurin inhibitors (TCIs) in vitiligo. The search strategy encompassed meta-analyses (MAs) and prospective multicentric cohort studies.</div></div><div><h3>Results</h3><div>Literature data – in particular three meta-analyses and one randomised controlled trial – confirm the superiority of tacrolimus versus placebo and its non-inferiority versus super-potent topical corticosteroids. In a subgroup analysis, tacrolimus suggests superior efficacy in children and in facial vitiligo. The combined use of tacrolimus and phototherapy exhibited synergistic efficacy.</div></div><div><h3>Conclusion</h3><div>Notwithstanding the market access of topical ruxolitinib, tacrolimus remains a viable treatment option for vitiligo, as substantiated by extant efficacy and safety in the literature. A recent decision of the French National Agency for the Safety of Medicines and Health Products (ANSM) authorized the compassionate prescription of tacrolimus and its reimbursement for patients.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103352"},"PeriodicalIF":3.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annales De Dermatologie Et De Venereologie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀